Pfizer/Neurocrine File First Indiplon NDA With Eye On Fourth Quarter 2005 Launch

Filing for immediate-release formulation of insomnia agent will be followed by extended-release submission in November, Neurocrine says. A simultaneous launch is planned. Firms are highlighting long-term use, middle-of-the-night dosing.